Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 20, Issue 24, 2002, Pages 4655-4664

  Ringden O ^a   Labopin, M ^a   Bacigalupo, A ^a   Arcese, W ^a   Schaefer, U W ^a   Willemze, R ^a   Koc, H ^a   Bunjes, D ^a   Gluckman, E ^a   Rocha, V ^a   Schattenberg, A ^a   Frassoni, F ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RELAPSE; RISK FACTOR; SIBLING; STEM CELL TRANSPLANTATION; THROMBOCYTE; TREATMENT OUTCOME; TREATMENT PLANNING;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; METHOTREXATE; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES;

EID: 0037115651     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.12.049     Document Type: Article

References (38)

1. Bensinger WI, Weaver CH, Appelbaum FR, et al: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 85:1655-1658, 1995
2. Körbling M, Przepiorka D, Huh YO, et al: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood 85:1659-1665, 1995
3. Schmitz N, Dreger P, Suttorp M, et al: Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (GCSF). Blood 85:1666-1672, 1995
4. Bensinger WI, Clift R, Martin P, et al: Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation. Blood 88:2794-2800, 1996
5. Champlin RE, Schmitz N, Chapius B, et al: Blood stem cells versus bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 95:3702-3709, 2000
6. Vigorito AC, Azevedo WM, Marques JF, et al: A randomised prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of hematological malignancies. Bone Marrow Transplant 22:1145-1151, 1998
7. Blaise D, Kuentz M, Fortanier C, et al: Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early stage leukemia: A report from the Société Francaise de Greffe de Moelle. J Clin Oncol 18:537-546, 2000
8. Heldal D, Tjonnfjord G, Brinch L, et al: A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 25:1129-1136, 2000
9. Powles R, Mehta R, Kulkami S, et al: Allogeneic blood and bonemarrow stem-cell transplantation in haematological malignant diseases: A randomised trial. Lancet 355:1231-1237, 2000
10. Bensinger W, Martin PJ, Storer B, et al: Transplantation of bone marrow as compared with peripheral blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344:175-181, 2001
11. Schmitz N, Bacigalupo A, Hasenclever D, et al: Allogeneic bone marrow transplantation vs. filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: First results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21:995-1003, 1998
12. Schmitz N, Beksac M, Hasenclever D, et al: A randomised study from the European Group for Blood and Marrow Transplantation comparing allogeneic transplantation of filgrastim-mobilised peripheral blood progenitor cells with bone marrow transplantation in 350 patients with leukemia. Blood 96:481, 2000 (abstr 2068)
13. Cutler C, Giri S, Jeyapalan S, et al: Acute and chronic graft-versushost disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: A meta-analysis. J Clin Oncol 19:3685-3691, 2001
14. Majolino I, Saglio G, Scime R, et al: High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant 17:555-560, 1996
15. Storek J, Gooley T, Siadak M, et al: Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graftversus-host disease. Blood 90:4705-4709, 1997
16. Elmaagacli AH, Beelen DW, Opalka B, et al: The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood 94:384-389, 1999
17. Ringdén O, Deeg HJ: Clinical spectrum of graft-versus-host disease, in Ferrara JLM, Deeg HJ, Burakoff S (eds): Graft vs Host Disease (ed 2). New York, NY, Marcel Dekker, Inc, 1996, pp 525-559
18. Clift R, Goldman JM, Gratwohl A, et al: Proposal for standardized reporting of bone marrow transplantation for leukemia. Bone Marrow Transplant 4:445-448, 1989
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
20. Cox DR: Regression models and life tables. J R Stat Soc 34:187-292, 1972
21. Nash RA, Pepe MS, Storb R, et al: Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 80:1838-1845, 1992
22. Ringdén O, Pihlstedt P, Markling L, et al: Prevention of graft-versushost disease with T-cell depletion or cyclosporin and methotrexate: A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 7:221-226, 1991
23. Hägglund H, Ringdén O, Remberger M, et al: Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow. Bone Marrow Transplant 22:131-136, 1998
24. Storb R, Prentice RL, Sullivan KM, et al: Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Int Med 98:461-466, 1983
25. Marmont A, Horowitz MM, Gale RP, et al: T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120-2130, 1991
26. Atkinson K, Horowitz MM, Van Bekkum DW, et al: Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 75:2459-2464, 1990
27. Storb R, Deeg HJ, Whitehead J, et al: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 314:729-735, 1986
28. Ringdén O, Horowitz MM, Sondel P, et al: Methotrexate, cyclosporine or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 81:1094-1101, 1993
29. Carlens S, Aschan J, Remberger M, et al: Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukemia. Bone Marrow Transplant 24:629-635, 1999
30. Glass B, Uharek L, Zeis M, et al: Allogeneic peripheral blood progenitor cell transplantation in a murine model: Evidence for an improved graft-versus-leukemia effect. Blood 90:1694-1700, 1997
31. Russell JA, Larratt L, Brown C, et al: Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: Influence of stem cell source on outcome. Bone Marrow Transplant 24:1177-1183, 1999
32. Weiden PL, Fluornoy N, Thomas ED, et al: Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 300:1068-1073, 1979
33. Horowitz MM, Gale RP, Sondel PM, et al: Graft-versus-leukemia reactions following bone marrow transplantation in humans. Blood 75:555-562, 1989
34. Ringdén O, Labopin M, Gluckman E, et al: Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Bone Marrow Transplant 18:921-929, 1996
35. Talmadge JE, Reed EC, Kessinger A, et al: Immunologic attributes of cytokine-mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant 17:101-109, 1996
36. Barrett AJ, Horowitz MM, Gale RP: Marrow transplantation for acute lymphoblastic leukemia: Factors affecting relapse and survival. Blood 74:862-871, 1989
37. Ringdén O, Zwaan FE, Hermans J, et al: European experience of bone marrow transplantation for leukemia. Transplant Proc 19:2600-2604, 1987
38. Appelbaum F: Allogeneic hematopoietic stem cell transplantation for acute leukemia. Semin Oncol 24:114-123, 1997